American College of Cardiology

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

REDUCE-AMI concluded beta-blockers show no significant benefit following myocardial infarction among patients with normal left ventricular ejection fraction

Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.

Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.

Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.

New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.

In this ACC.24 episode of Don't Miss a Beat, hosts are joined by Javed Butler, MD, for a breakdown of the EMPACT-MI trial.

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.

Join us April 01 on Twitter for a pre-meeting Tweet chat ahead of the American College of Cardiology's 2024 annual meeting!

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

Erin Michos, MD, MHS, discusses her choices for top studies in lipidology from the American College of Cardiology 2023 Scientific Sessions.

New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.

Gregg W. Stone, MD, discussed the 5-year findings of the COAPT trial and provided insight into the benefit of the transcatheter procedure in high-risk patients with heart failure.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

An analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials provides insight into the atherosclerotic cardiovascular risk associated with high-sensitivity C-reactive protein.

In an interview at ACC 2023, Safia Chatur, MD provided insight into the analysis of the PARADIGM-HF and PARAGON-HF trials, suggesting early eGFR changes should not deter continuation of sacubitril/valsartan.

Viet Le, PA-C, offers perspective on a study from Intermountain Healthcare reporting on the epidemiology, relationship to ASCVD risk factors, and clinical outcomes associated with Lp(a) in real-world settings.

Deepak Bhatt, MD, MPH, discusses results of the phase 2 ENTRIGUE trial and how it informs clinicians on the effects of the human FGF21 analogue in patients with severe hypertriglyceridemia.

New research from a phase 2b trial presented at ACC 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular disease.

Hear from Deepak Bhatt, MD, MPH, as he discusses how he interprets the results of the HALO trial and offers perspective on the forthcoming research related to baxdrostat.

At ACC 2023, results from the RAPID-HF trial reported atrial pacing was ineffective at improving exercise capacity in patients with HFpEF and chronotropic incompetence.

Results from the phase 3 A DUE study suggest a combination of macitentan and tadalafil nearly doubled reductions in pulmonary vascular resistance in patients with PAH.

Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.

Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.

In an interview at ACC 2023, Ankeet Bhatt, MD, describes how virtual care team represents an effective and scalable approach to improve therapeutic optimization across a health system.

Data from COORDINATE-Diabetes presented at ACC 2023 demonstrate the impact of a multifaceted, coordinated care approach on improving prescription rates of statins, ACEs/ARBs, and glucose-lowering medications among people with type 2 diabetes.

Mary McGowan, MD, discusses a study she presented examining the overall prevalence of patients with high-risk hypercholesterolemia who fail to meet guideline-recommended goals for LDL-C levels.